DNA damage response alterations in ovarian cancer: From molecular mechanisms to therapeutic opportunities
M Ovejero-Sanchez, R Gonzalez-Sarmiento… - Cancers, 2023 - mdpi.com
Simple Summary The DNA damage response (DDR) is frequently altered in ovarian cancer
(OC), which can be exploited for therapeutic purposes. Moreover, targeting DDR signaling …
(OC), which can be exploited for therapeutic purposes. Moreover, targeting DDR signaling …
Combination of talazoparib and palbociclib as a potent treatment strategy in bladder cancer
FG Klein, C Granier, Y Zhao, Q Pan, Z Tong… - Journal of Personalized …, 2021 - mdpi.com
The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for
cancer therapy. Due to the complex molecular network that regulates cell cycle progression …
cancer therapy. Due to the complex molecular network that regulates cell cycle progression …
Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review
N Abbas, L Chehade… - Therapeutic Advances in …, 2024 - journals.sagepub.com
Bladder cancer (BC) poses a significant health challenge, particularly in metastatic cases,
where the prognosis is unfavorable and therapeutic options are limited. Poly ADP-ribose …
where the prognosis is unfavorable and therapeutic options are limited. Poly ADP-ribose …
[图书][B] Biomarkers of Therapeutic Response in Bladder Cancer
AE Goodspeed - 2018 - search.proquest.com
Abstract Treatment of muscle-invasive bladder cancer (MIBC) typically includes systemic
cisplatin-based chemotherapy. Despite being a mainstay first-line treatment for 3 decades …
cisplatin-based chemotherapy. Despite being a mainstay first-line treatment for 3 decades …